Alexandra D. Carides
Alexandra D. Carides
Affiliation inconnue
Adresse e-mail validée de temple.edu
Titre
Citée par
Citée par
Année
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial …
PJ Hesketh, SM Grunberg, RJ Gralla, DG Warr, F Roila, R De Wit, ...
Journal of Clinical Oncology 21 (22), 4112-4119, 2003
8542003
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting: results from a …
S Poli‐Bigelli, J Rodrigues‐Pereira, AD Carides, G Julie Ma, K Eldridge, ...
Cancer 97 (12), 3090-3098, 2003
6312003
Reduction of cisplatin-induced emesis by a selective neurokinin-1–receptor antagonist
RM Navari, RR Reinhardt, RJ Gralla, MG Kris, PJ Hesketh, A Khojasteh, ...
New England Journal of Medicine 340 (3), 190-195, 1999
4201999
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists
PJ Hesketh, S Van Belle, M Aapro, FD Tattersall, RJ Naylor, ...
European journal of cancer 39 (8), 1074-1080, 2003
2892003
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone
D Campos, JR Pereira, RR Reinhardt, C Carracedo, S Poli, C Vogel, ...
Journal of clinical oncology 19 (6), 1759-1767, 2001
2652001
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized …
BL Rapoport, K Jordan, JA Boice, A Taylor, C Brown, JS Hardwick, ...
Supportive Care in Cancer 18 (4), 423-431, 2010
2622010
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
SP Chawla, SM Grunberg, RJ Gralla, PJ Hesketh, C Rittenberg, ME Elmer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
2562003
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial
JS Solomkin, AE Yellin, OD Rotstein, NV Christou, EP Dellinger, ...
Annals of surgery 237 (2), 235, 2003
2522003
Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist
BJ Kopp, M Mrsan, BL Erstad, JJ Duby
American Journal of Health-System Pharmacy 64 (23), 2483-2487, 2007
2092007
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE
S Grunberg, D Chua, A Maru, J Dinis, S DeVandry, JA Boice, JS Hardwick, ...
Journal of Clinical Oncology 29 (11), 1495-1501, 2011
2062011
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting
TJ Gan, CC Apfel, A Kovac, BK Philip, N Singla, H Minkowitz, AS Habib, ...
Anesthesia & Analgesia 104 (5), 1082-1089, 2007
1992007
Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin …
R De Wit, J Herrstedt, B Rapoport, AD Carides, G Carides, M Elmer, ...
Journal of clinical oncology 21 (22), 4105-4111, 2003
1712003
The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a …
R de Wit, J Herrstedt, B Rapoport, AD Carides, J Guoguang-Ma, M Elmer, ...
European Journal of Cancer 40 (3), 403-410, 2004
1662004
The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo …
DG Warr, SM Grunberg, RJ Gralla, PJ Hesketh, F Roila, R De Wit, ...
European Journal of Cancer 41 (9), 1278-1285, 2005
1622005
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients …
PJ Hesketh, M Aapro, JC Street, AD Carides
Supportive care in cancer 18 (9), 1171-1177, 2010
1612010
Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869: a randomized controlled trial
S Van Belle, MR Lichinitser, RM Navari, AM Garin, MLA Decramer, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2002
1572002
Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind Phase III trial in patients undergoing open …
P Diemunsch, TJ Gan, BK Philip, MJ Girao, L Eberhart, MG Irwin, J Pueyo, ...
British journal of anaesthesia 99 (2), 202-211, 2007
1562007
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
V Cocquyt, S Van Belle, RR Reinhardt, MLA Decramer, M O'brien, ...
European journal of cancer 37 (7), 835-842, 2001
1562001
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial
YC Cohen, KS Liu, NL Heyden, AD Carides, KM Anderson, AG Daifotis, ...
Journal of the National Cancer Institute 99 (18), 1366-1374, 2007
1352007
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
S Shahinfar, RL Simpson, AD Carides, B Thiyagarajan, Y Nakagawa, ...
Kidney international 56 (5), 1879-1885, 1999
1341999
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20